An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971)… Read on
Oregon State University researchers have found that using nanotechnology with heat and cytotoxic drugs can kill up to 95% of ovarian cancer cells… Read on
A new study released in Lancet Oncology showed that abnormal levels of female hormones in the bloodstream may be why women with BRCA1 or BRCA2 mutations are at a higher risk for breast and ovarian cancer and not other cancers… Read on
A new study conducted by Cancer Research UK has identified chemical “tags” on DNA in patients’ tumors that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive… Read on
A study led by Dr. Andrew Stephens from the Prince Henry’s Institute has discovered a process that is associated with inflammation in cancers. This discovery could lead to expanded treatment options for some types of ovarian cancer tumors… Read on
The European Cancer Congress convened in Amsterdam, the Netherlands from September 27 – October 1, 2013. The European Cancer Congress in the main multidisciplinary and multi-professional educational meeting in oncology to take place in Europe… Read on
Research published in Sept. 2013 in the Journal of Clinical Oncology show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients… Read on
Dr. Ron Chandler is a 2013 Ann Schreiber Mentored Investigator Award recipient. In this interview with OCRF’s Sarah DeFeo, Dr. Chandler discusses his research and what it means to receive a grant from OCRF… Read on
A new study released today by MD Anderson Cancer Center in Texas shows that a family of microRNAs (miR-200) blocks cancer progression by cutting off the tumor’s ability to build new blood vessels… Read on
Washington, DC—A new report released by the Ovarian Cancer National Alliance summarizes the experiences of 1,014 women diagnosed with ovarian cancer… Read on
